Pictet Asset Management
RNAM

Pictet Asset Management’s Avidity Biosciences RNAM Stock Holding History

Pictet Asset Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-83,712
Closed -$6.04M – 2165
2025
Q4 		$6.04M Sell
83,712
-1,254,379
-94% -$81M 0.01% 772
2025
Q3 		$58.2M Buy
1,338,091
+370,489
+38% +$15M 0.06% 293
2025
Q2 		$27.5M Buy
967,602
+94,380
+11% +$2.81M 0.03% 431
2025
Q1 		$25.8M Buy
873,222
+74,194
+9% +$2.31M 0.03% 429
2024
Q4 		$23.2M Buy
799,028
+12,548
+2% +$524K 0.03% 463
2024
Q3 		$36.1M Buy
786,480
+406,678
+107% +$17.6M 0.04% 351
2024
Q2 		$15.5M Buy
379,802
+368,930
+3,393% +$10.6M 0.02% 535
2024
Q1 		$277K Buy
+10,872
New +$170K ﹤0.01% 1581

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

Pictet Asset Management's RNAM Position: Q1 2026 in Review

Pictet Asset Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 83,712 shares — an estimated $6.04M sold.

Pictet Asset Management first reported a position in RNAM in Q1 2024 and held it in 8 quarters. The position peaked at $58.2M in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Pictet Asset Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Pictet Asset Management sold 83,712 Avidity Biosciences shares in Q1 2026, an estimated $6.04M.
  • Pictet Asset Management first reported a position in Avidity Biosciences in Q1 2024 and held it in 8 quarters.
  • Pictet Asset Management's Avidity Biosciences position peaked at $58.2M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.